Zydus Cadila gets final approval for Spironolactone Tablets USP
Zydus Cadila has received final approval from the USFDA to market Spironolactone Tablets USP (US RLD - Aldactone Tablets). The strength of the said tablets is of 25 mg, 50 mg and 100 mg. The drug will be manufactured at the group’s manufacturing facility at Baddi.
The medicine is used to treat high blood pressure and heart failure. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. It can also be used for treating swelling i.e. edema caused by certain conditions like heart failure and liver disease by removing excess fluid and improving symptoms such as the breathing problems.
Earlier, on Thursday, the company had received final approval from USFDA for marketing Piroxicam Capsules USP (US RLD - Feldene Capsules) in strengths of 10 mg and 20 mg. The said drug would be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.
This medicine is a non-steroidal anti-inflammatory drug to be used for symptomatic treatment of osteoarthritis and rheumatoid arthritis. With this new approval, the company has now 210 approvals and has filed for 330 ANDAs till date.
Since past 15 days, the stock has corrected by ~13 percent. On Thursday, it had closed at Rs. 343.30 per share. On Friday, it opened at Rs. 343 and made intra-day high of Rs. 346.70 and intra-day low of Rs. 334.80 in the morning trading session.